Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 25,204 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy Adult Participants, Healthy Participants
Interventions
Magnetic Resonance Imaging (MRI), Broad thalamic stimulation (TI-TES), Carrier only SHAM stimulation, Anterior thalamic stimulation (TI-TES), Posterior thalamic stimulation (TI-TES)
Other · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions
GTB-5550
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Neurogenic Bowel
Interventions
Peristeen
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Bowel Preparation
Interventions
CLENPIQ, MIRALAX, SENNA
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
12 Months to 8 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Mobile, Alabama • San Diego, California • Baltimore, Maryland
Conditions
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
Interventions
SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

tDCS-Augmented Exposure Therapy for Pathological Fear

NCT03095482
Conditions
Specific Phobias
Interventions
Transcranial Direct Current Stimulation (tDCS), In vivo exposure therapy
Device · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Terminated Phase 4 Interventional Results available

Theramine® in the Prevention of Migraine Headache

NCT01944059
Conditions
Migraine Headaches
Interventions
Theramine (medical food/old drug), Placebo (l-alanine)
Drug · Other
Lead sponsor
Vincent Martin, MD
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Obesity, Weight Change, Body, Weight Loss, Physical Activity
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Timeline
2009 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Reminders to Complete HPV Series

NCT01731496
Conditions
Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
Interventions
Telephone reminder, Text Message reminder
Other
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 21 Years
Enrollment
749 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Rochester, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Treatment of Anxiety in Late Adolescents With Autism

NCT02977962
Conditions
Autism Spectrum Disorder
Interventions
Cognitive-Behavior Therapy, Treatment as Usual
Behavioral · Other
Lead sponsor
University of South Florida
Other
Eligibility
16 Years to 21 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
St. Petersburg, Florida
Conditions
Salivary Gland Tumor
Interventions
MRI
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Mandibular Advancement Device and Changes in Nocturia

NCT05562388
Conditions
Obstructive Sleep Apnea, Nocturia, OSA
Interventions
Somnodent Classic
Device
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
St. Petersburg, Florida • Boston, Massachusetts
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
alemtuzumab, graft-versus-tumor induction therapy, rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
40 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
plerixafor, filgrastim, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diabetes Mellitus Type 2
Interventions
DREAM
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers

Outcomes After Weight Loss Surgery in Low-Risk Patients

NCT05699083
Conditions
Weight Loss, Bariatric Surgery
Interventions
Body Image/Self-Esteem Questionnaires
Other
Lead sponsor
Dr. Feiz & Associates
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Recurrent Glioblastoma
Interventions
CART-EGFR-IL13Ra2 T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting Not applicable Interventional Accepts healthy volunteers

Music Use in Parturients Admitted to Labor & Delivery

NCT06969105
Conditions
Anxiety, Pain, Patient Satisfaction
Interventions
Music
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Duarte, California • Jacksonville, Florida • Greenlawn, New York